Redeye trims its forecast following Q3’26 figures, which posted healthy progress although somewhat b...
Ahead of NoHo Partners' Q3 2026 report, due on 3 November, we make small negative estimate revisions...
Redeye comments on Vertiseit's Q3 report, showing ARR ahead of our forecast with accelerating organi...
Redeye lowers its Base Case to SEK339 (354) as a higher risk-free rate in our WACC offsets 3% higher...
ATOSS will release preliminary Q3 figures on Friday.
Bittium publishes its Q3 business review on Thursday, 29 October.
Redeye provides a short comment on the recent press release announcing that the CADScor System has r...
Redeye comments on Lime’s Q3 report, which delivered ARR in line with our forecast alongside a beat ...
Redeye updates its estimates ahead of Hacksaw’s Q3-results (due 3 November) where we align our forec...
* Sales SEK 42m (-15% vs. ABGSCe), EBIT -6.6m (ABGSCe -2.
Plejd fortsatte att kombinera hög tillväxt med förbättrad lönsamhet under Q3’26.
* Demand stabilising, but reduction in FTEs a headwind * We cut adj.
Q3 should show firmer earnings momentum at EUZ. Recovering Isotope Products profitability is set to ...
BioInvent published its ESMO 2026 abstract for BI-1808 plus pembrolizumab in platinum-resistant ovar...
Truecaller's preliminary Q3 figures beat both our preview and consensus.
Plejd beat our Q3 estimates on net sales (+5%) and EBIT (+23%), but Norwegian restocking flatters th...
* Q3e EBITDA of NOK 10m, top line flat q-o-q * Meijer kicks off the US opportunity * Fair value rang...
Studsvik has signed a long-term framework agreement with Norwegian Nuclear Decommissioning to manage...
Redeye strengthens its positive view of q.beyond following solid Q3 new sales figures, driven mainly...
Flow-through financing of CAD 5.0 million successfully completed Antimony Resources Corp.